The Business Case for Product Carbon Footprints in Pharma

Why pharmaceutical buyers now ask for product carbon footprints

Corporate sustainability reports tell you how much a company emits. However, they do not tell you whether one batch of antibiotics creates more greenhouse gas than another. For pharmaceutical supply chains, that distinction now matters commercially.

Product carbon footprints give buyers the data they need to compare climate impact at the item level. Consequently, suppliers who can provide credible numbers may win tenders that others lose. This shift reflects a broader change in how healthcare procurement teams evaluate environmental performance.

The pharmaceutical sector accounts for roughly 25% of healthcare’s total greenhouse-gas emissions, according to the Climate Action Accelerator. Meanwhile, about 71% of healthcare emissions come from supply chains, including pharmaceutical production and transport. Therefore, reducing procurement emissions requires item-level carbon footprint information rather than company-wide figures alone.

Most pharmaceutical emissions sit in the supply chain rather than in direct operations. As a result, buyers increasingly ask suppliers for product-level data to support purchasing decisions. This creates both pressure and opportunity for manufacturers who can measure and reduce the carbon intensity of individual products.

The NHS Environmental Impact Rating and industry response

In January 2022, the NHS proposed an Environmental Impact Rating system for pharmaceutical products. The proposal marked a significant shift toward product-level environmental assessment in public-sector procurement. Biophorum-supported work subsequently called for license holders, contract development and manufacturing organisations, and key suppliers to develop a common framework for sharing product carbon footprint data.

The European Federation of Pharmaceutical Industries and Associations has called for standardisation and harmonisation of pharmaceutical product carbon footprint assessment. Industry interest in comparable methods is growing because buyers need consistent metrics to compare suppliers. Without standardised protocols, one manufacturer’s carbon footprint may not mean the same thing as another’s.

Product carbon footprints are described as a key metric for value-chain transparency. They can help identify climate-impact hotspots in manufacturing processes and support pathways toward net-zero targets. For example, a high footprint in solvent production might prompt process redesign or supplier substitution.

McKinsey reports that the pharmaceutical sector still lacks standardised measurement and reporting protocols for product carbon footprints. This absence makes transparency between active pharmaceutical ingredient suppliers and pharmaceutical customers difficult. Different life-cycle assessment boundaries, emission factors, and allocation methods produce results that cannot easily be compared.

How product carbon footprints differ from corporate reporting

Corporate-level carbon reporting shows total emissions across an organisation. Product carbon footprints show emissions attributable to a specific item, batch, or formulation. The difference matters because buyers need to know which products carry lower climate impact.

A pharmaceutical company might report 50,000 tonnes of Scope 1, 2, and 3 emissions annually. However, that figure does not tell a procurement team whether Product A generates twice the emissions of Product B. Product carbon footprints fill that gap by allocating emissions to individual items.

This granularity allows buyers to factor carbon intensity into sourcing decisions. For instance, two suppliers might offer chemically identical active ingredients at similar prices. If one supplier provides a credible product carbon footprint showing 30% lower emissions, that data can tip the procurement decision.

Product-level data also helps suppliers demonstrate the impact of emission-reduction efforts. A manufacturer that switches to renewable energy or redesigns a synthesis route can show buyers the carbon benefit at the product level. Corporate reporting alone cannot capture that operational detail.

Supply chain emissions and pharmaceutical manufacturing

Most pharmaceutical emissions occur outside direct operations. Raw materials, energy for synthesis, solvent production, packaging, and transport all contribute to a product’s total carbon footprint. Therefore, reducing emissions requires collaboration across the supply chain.

Active pharmaceutical ingredient manufacturing is particularly carbon-intensive. Complex synthesis routes, high-purity requirements, and solvent use all drive emissions higher. McKinsey analysis suggests API manufacturers can cut emissions by up to 90% by 2040 using specific decarbonisation methods.

Green chemistry reduces hazardous substances and waste in chemical processes. Process redesign can eliminate unnecessary steps or substitute lower-emission reagents. Solvent recovery systems capture and reuse solvents rather than incinerating or disposing of them. Each method reduces the carbon intensity of the final product.

Supplier collaboration is equally important. Pharmaceutical companies rely on contract manufacturers, packaging suppliers, and logistics providers. If those partners cannot measure or reduce their emissions, the product carbon footprint will remain high regardless of internal efforts.

Renewable energy procurement offers another reduction lever. Switching from grid electricity to certified renewable power can significantly lower Scope 2 emissions. Some manufacturers also pursue on-site generation through solar panels or biogas installations.

Pharmaceutical product carbon footprints in procurement decisions

• Product carbon footprints allow buyers to compare the climate impact of specific pharmaceutical items rather than relying on company-wide emissions data.
• The NHS proposed an Environmental Impact Rating system in January 2022, signalling that public-sector procurement will increasingly factor environmental performance into purchasing decisions.
• Approximately 71% of healthcare emissions come from supply chains, including pharmaceutical production and transport, making supplier-level data critical for emission reductions.
• McKinsey reports that active pharmaceutical ingredient manufacturers can reduce emissions by up to 90% by 2040 through green chemistry, process redesign, solvent recovery, and supplier collaboration.
• The pharmaceutical sector currently lacks standardised measurement and reporting protocols for product carbon footprints, which complicates comparisons between suppliers.
• Suppliers who provide credible product carbon footprint data may gain a competitive advantage as sustainability criteria become more common in procurement processes.
• The European Federation of Pharmaceutical Industries and Associations has called for standardisation and harmonisation of pharmaceutical product carbon footprint assessment to enable meaningful comparisons.

What this means for pharmaceutical suppliers and manufacturers

Suppliers who can measure and report product carbon footprints will be better positioned as procurement criteria evolve. Buyers increasingly ask for item-level emissions data during tender processes. Therefore, manufacturers unable to provide credible figures may lose business to competitors who can.

Measuring product carbon footprints requires life-cycle assessment capability. Organisations must track emissions from raw material extraction through manufacturing, packaging, and transport. This involves collecting data from suppliers, measuring energy use, and applying appropriate emission factors.

Many suppliers lack the internal expertise to conduct robust life-cycle assessments. Consequently, they may need external support to develop credible methodologies and gather the necessary data. Our compliance services for carbon reporting help manufacturers build the systems needed to produce defensible product carbon footprints.

Standardisation remains a challenge. Different life-cycle assessment methods produce different results, making it hard for buyers to compare suppliers. Industry bodies are working toward common frameworks, but adoption will take time. In the meantime, suppliers should document their methodology clearly so buyers understand what the numbers represent.

Emission reduction is equally important. A high product carbon footprint becomes a commercial liability if competitors offer lower-impact alternatives. Therefore, manufacturers should identify reduction opportunities in their processes, energy sources, and supply chains. Even incremental improvements can provide a procurement advantage.

The Climate Action Accelerator recommends that suppliers adopt renewable energy, develop decarbonisation plans, and provide product carbon footprints or life-cycle assessments to support lower-emission purchasing decisions. These actions address both measurement and reduction, positioning suppliers to meet emerging buyer expectations.

For contract manufacturers, product carbon footprints create both risk and opportunity. If a CDMO cannot measure or reduce emissions, pharmaceutical customers may move production to lower-impact facilities. Conversely, CDMOs that invest in measurement and reduction can differentiate themselves in a competitive market.

Green chemistry and process redesign in pharmaceutical production

Green chemistry principles aim to reduce or eliminate hazardous substances in chemical processes. In pharmaceutical manufacturing, this often means redesigning synthesis routes to use safer reagents, generate less waste, or operate at lower temperatures and pressures.

Process redesign can cut both emissions and costs. For example, replacing a six-step synthesis with a four-step route reduces solvent use, energy consumption, and waste disposal. The carbon footprint falls, and manufacturing becomes more efficient.

Solvent recovery systems capture solvents for reuse rather than disposal. Pharmaceutical synthesis uses large volumes of organic solvents, many of which are incinerated or sent to hazardous waste facilities. Recovery reduces both emissions and raw material costs. However, the business case depends on solvent price, recovery efficiency, and capital investment.

Some manufacturers have redesigned processes to use water or bio-based solvents instead of petroleum-derived alternatives. This substitution can lower the product carbon footprint significantly, particularly if the bio-based solvent comes from waste streams or sustainable feedstocks.

Renewable energy procurement reduces Scope 2 emissions without changing manufacturing processes. Nevertheless, switching to certified renewable power requires long-term contracts or on-site generation. Many pharmaceutical sites operate in industrial areas where rooftop solar may be limited, so off-site power purchase agreements often provide the most practical route.

Measurement challenges and emerging standards

Life-cycle assessment for pharmaceuticals is technically complex. Active ingredients pass through multiple synthesis steps, each with different reagents, solvents, and energy inputs. Packaging, sterilisation, and cold-chain transport add further emissions. Allocating all these impacts to a single product requires detailed data and careful methodology.

Emission factors vary by region and energy source. Manufacturing the same product in Germany and India will produce different carbon footprints because grid electricity in each country has different emission intensities. Suppliers must account for these regional differences to produce accurate figures.

Scope 3 emissions present particular challenges. Upstream emissions from raw material suppliers, downstream emissions from product use and disposal, and transport emissions all fall under Scope 3. Pharmaceutical companies often lack direct data from suppliers, forcing them to rely on industry averages or estimates.

Industry bodies are working toward standardised methods. The European Federation of Pharmaceutical Industries and Associations has called for harmonisation of product carbon footprint assessment. Standardisation would allow buyers to compare suppliers on a like-for-like basis, making product carbon footprints more useful in procurement.

Our net-zero program for carbon reporting compliance supports organisations developing robust measurement systems for Scope 1, 2, and 3 emissions. This foundation is essential for credible product carbon footprints that withstand buyer scrutiny.

Authoritative guidance and further detail

The Greener NHS programme published by NHS England outlines the health service’s pathway to net zero and explains how procurement will support emission reductions across the supply chain.

The Climate Action Accelerator, developed by the Council for Interior Design Excellence, provides practical guidance on requesting product carbon footprints and life-cycle assessments from suppliers in various sectors, including healthcare.

The ISO 14067:2018 standard specifies requirements and guidelines for quantifying and communicating the carbon footprint of products. This international standard provides a technical foundation for credible product carbon footprint assessments.

Finally, the Greenhouse Gas Protocol Product Life Cycle Accounting and Reporting Standard offers detailed guidance on calculating emissions associated with individual products throughout their life cycles. Many pharmaceutical companies use this framework as the basis for product carbon footprint methodologies.